EuropaBio

IMAGIO consortium receives Innovative Health Initiative EUR 24 million grant to improve cancer treatments

Retrieved on: 
Thursday, June 15, 2023
COCIR, Delft University of Technology, Thermosome, University Medical Center Utrecht, Sarcoma, VU, ETH, University Medical Center, Newcastle upon Tyne Hospitals NHS Foundation Trust, Cancer, Lung cancer, JU, MedTech Europe, Research, Immunotherapy, Teaching hospital, Liver cancer, NYSE, Turku University Hospital, EFPIA, MRI, Radboud University Medical Center, Radiation, Philips, Vrije Universiteit Amsterdam, IHI, Doxorubicin, Interventional oncology, AEX, Liver, Diagnosis, PHG, Death, LUMC, EuropaBio, Pharmaceutical industry, Medical imaging, European, Pfizer

The Innovative Health Initiative has awarded a EUR 24 million grant to the IMAGIO consortium of clinical partners coordinated by Philips, with additional resources and funding from industry partners

Key Points: 
  • The Innovative Health Initiative has awarded a EUR 24 million grant to the IMAGIO consortium of clinical partners coordinated by Philips, with additional resources and funding from industry partners
    The consortium will carry out research into improving clinical outcomes through less invasive treatments for lung cancer, liver cancer and soft tissue sarcomas
    Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the Philips-coordinated IMAGIO consortium [1] of clinical partners has been awarded a EUR 24 million Innovative Health Initiative (IHI) grant, complemented with additional resources and funding from industry partners [2], to carry out research into less invasive cancer treatments.
  • Consisting of approximately 30 partners, the consortium will use the funding to improve clinical outcomes with interventional oncology innovations focused on lung cancer, liver cancer and soft tissue sarcomas.
  • In Europe about 2.7 million people are diagnosed with cancer each year [3].
  • This project is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112053.

Europe’s Early-Stage Life Sciences Venture Capitalists Unveil Advocacy Organisation to Drive Innovation and Investment in Health Care

Retrieved on: 
Monday, October 4, 2021
Professional Services, Health, Finance, General Health, Research, Science, Biotechnology, Policy, Human, Research, Association of British HealthTech Industries, German, Economics, Incubator, Patient, Advisory Council, VCS, Cornelia Yzer, Awareness, EuropaBio, Acceleration, Ecosystem, Government, Industry, United Kingdom, Pharmaceutical industry

Today, at the HealthTech Innovations Days in Paris, the Life Sciences Acceleration Alliance (LSAA) advocacy coalition was announced to industry leaders and life science venture capitalists (VCs).

Key Points: 
  • Today, at the HealthTech Innovations Days in Paris, the Life Sciences Acceleration Alliance (LSAA) advocacy coalition was announced to industry leaders and life science venture capitalists (VCs).
  • The new non-profit coalition, driven by the life sciences organisations and investors, will advocate for public policies that strengthen Europes early-stage life science ecosystem and drive innovation.
  • The coalition will focus on informing policymakers on the unique and complex partnerships that drive medical innovation and investment for new medical treatments for patients.
  • Life Sciences Acceleration Alliance is a coalition of investors, scientific and corporate leaders dedicated to strengthening life sciences research and development in Europe.

Biomaterials Company MycoWorks Appoints Board Director Tjerk de Ruiter

Retrieved on: 
Wednesday, May 12, 2021
MycoWorks, EuropaBio, Mycelium, Biology, Organizations, Organisms

b'SAN FRANCISCO, May 12, 2021 /PRNewswire/ -- Biomaterials company MycoWorks today announced the appointment of independent Board Director Tjerk de Ruiter, who joins MycoWorks Board Directors Anders Spohr (Novo Holdings), Kiersten Stead (DCVC Bio), and MycoWorks CEO Matt Scullin.

Key Points: 
  • b'SAN FRANCISCO, May 12, 2021 /PRNewswire/ -- Biomaterials company MycoWorks today announced the appointment of independent Board Director Tjerk de Ruiter, who joins MycoWorks Board Directors Anders Spohr (Novo Holdings), Kiersten Stead (DCVC Bio), and MycoWorks CEO Matt Scullin.
  • De Ruiter also serves as advisor to Novo Holdings and is a board member at NuTek Food Science, with prior positions as Chairman of EuropaBio and the BIO I&E Section Governing Board.\n"The advanced work that the MycoWorks team is leading through the combination of biotechnology, materials and applied science, and craftsmanship has created a unique opportunity for the company to provide new material solutions that brands and consumers are demanding.
  • Materials are grown to brand partners\' specifications for performance, aesthetic features and more, unlocking new design possibilities for the fashion and footwear industries.\nFor more information, please visit MycoWorks.com or contact:\nIn 2013, co-founders Philip Ross and Sophia Wang formed MycoWorks, a San Francisco based biomaterials company dedicated to bringing new mycelium materials to the world.
  • MycoWorks\' patented Fine Mycelium technology is an advanced manufacturing platform and breakthrough in materials science, which engineers mycelium during growth to form proprietary, interlocking cellular structures for unparalleled strength and durability.\n'

CohBar to Present at the BIO Investor Forum

Retrieved on: 
Monday, October 5, 2020
Life sciences, Articles, Biotechnology, Environmental biotechnology, BIOTEC, Biotechnology Innovation Organization, EuropaBio

This presentation will be available on demand for BIO Investor attendees.

Key Points: 
  • This presentation will be available on demand for BIO Investor attendees.
  • BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.
  • BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
  • BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.